Jens H Kuhn Selected Research

Vaccines

1/2022	Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses.
1/2022	Challenges and Opportunities in the Use of High and Maximum Biocontainment Facilities in Developing and Licensing Risk Group 3 and Risk Group 4 Agent Veterinary Vaccines.
10/2020	Animal models for COVID-19.
1/2020	A Forgotten Episode of Marburg Virus Disease: Belgrade, Yugoslavia, 1967.
1/2020	A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic Region.
1/2020	Post-exposure prophylactic vaccine candidates for the treatment of human Risk Group 4 pathogen infections.
1/2019	The ReFRAME library as a comprehensive drug repurposing library to identify mammarenavirus inhibitors.
11/2018	Recombinant Lassa Virus Expressing Green Fluorescent Protein as a Tool for High-Throughput Drug Screens and Neutralizing Antibody Assays.
1/2016	Ebola virus disease candidate vaccines under evaluation in clinical trials.
7/2015	Middle East respiratory syndrome: obstacles and prospects for vaccine development.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jens H Kuhn Research Topics

Disease

33	Infections 03/2024 - 10/2004
9	Ebola Hemorrhagic Fever 11/2022 - 09/2011
5	COVID-19 11/2023 - 01/2020
5	Fever (Fevers) 01/2018 - 03/2007
4	Lassa Fever (Fever, Lassa) 10/2023 - 11/2018
3	Neoplasms (Cancer) 03/2024 - 12/2013
3	Communicable Diseases (Infectious Diseases) 01/2021 - 01/2015
3	Viral Hemorrhagic Fevers (Viral Hemorrhagic Fever) 01/2017 - 06/2011
2	Convalescence 01/2022 - 01/2017
2	Emerging Communicable Diseases (Emerging Infectious Diseases) 01/2022 - 02/2016
1	Mpox (monkeypox) 04/2024
1	Primate Diseases 04/2024
1	Disease Progression 01/2023
1	Uveitis 11/2022
1	Viremia 11/2022
1	Zoonoses 01/2022
1	Lung Diseases (Lung Disease) 01/2022
1	Calculi (Calculus) 01/2022
1	Rubella (German Measles) 10/2020
1	Poliomyelitis (Polio) 01/2020
1	Nairobi Sheep Disease 10/2016
1	Bronchitis 04/2016
1	Alphavirus Infections 03/2016
1	Necrosis 02/2016
1	Lethargy 02/2016
1	Coronavirus Infections 07/2015
1	Virus Diseases (Viral Diseases) 02/2015
1	Vesicular Stomatitis 11/2014
1	Crimean Hemorrhagic Fever 05/2011

Drug/Important Bio-Agent (IBA)

12	VaccinesIBA 01/2022 - 06/2006
11	Proteins (Proteins, Gene)FDA Link 03/2024 - 10/2004
8	Glycoproteins (Glycoprotein)IBA 01/2020 - 10/2004
7	Antiviral Agents (Antivirals)IBA 11/2022 - 08/2011
4	Monoclonal AntibodiesIBA 04/2024 - 09/2015
3	RNA (Ribonucleic Acid)IBA 11/2022 - 01/2017
3	AntibodiesIBA 01/2022 - 01/2014
3	Indicators and Reagents (Reagents)IBA 04/2020 - 01/2016
3	EnzymesIBA 01/2019 - 10/2004
3	Transferrin Receptors (Transferrin Receptor)IBA 12/2013 - 03/2007
2	Biomarkers (Surrogate Marker)IBA 11/2023 - 01/2020
2	Neutralizing AntibodiesIBA 01/2022 - 02/2016
2	Attenuated VaccinesIBA 01/2020 - 01/2020
2	InterferonsIBA 01/2019 - 01/2011
2	CytokinesIBA 01/2019 - 01/2016
2	Ribavirin (Virazole)FDA LinkGeneric 01/2019 - 11/2018
2	RestonIBA 01/2017 - 09/2011
2	Small Interfering RNA (siRNA)IBA 03/2016 - 09/2013
2	Phosphotransferases (Kinase)IBA 02/2015 - 07/2014
2	AerosolsIBA 01/2015 - 01/2014
2	Peptides (Polypeptides)IBA 09/2011 - 05/2011
1	3- (2- methoxyphenyl)- 5- methoxy- 1,3,4- oxadiazol- 2(3H)- oneIBA 04/2024
1	DNA-Directed DNA Polymerase (Polymerases, DNA)IBA 03/2024
1	Cysteine (L-Cysteine)FDA Link 03/2024
1	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 03/2024
1	Anti-Infective Agents (Microbicides)IBA 10/2023
1	Contrast MediaIBA 01/2023
1	Viral AntigensIBA 11/2022
1	sangivamycinIBA 11/2022
1	remdesivirIBA 11/2022
1	Complement System Proteins (Complement)IBA 01/2022
1	RG-4 (RG 4)IBA 01/2022
1	Viral RNAIBA 01/2022
1	Complementary DNA (cDNA)IBA 01/2021
1	Immunotoxins (Immunotoxin)IBA 01/2021
1	enhanced green fluorescent proteinIBA 01/2021
1	Capsid Proteins (Capsid Protein)IBA 10/2020
1	EpitopesIBA 10/2020
1	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 10/2020
1	Codon (Codons)IBA 01/2020
1	NucleosidesIBA 01/2019
1	purineIBA 01/2019
1	Monocyte Chemoattractant ProteinsIBA 01/2019
1	Electron Transport Complex III (Coenzyme Q-Cytochrome-c Reductase)IBA 01/2019
1	pyrimidineIBA 01/2019
1	InterleukinsIBA 01/2019
1	favipiravirIBA 11/2018
1	Green Fluorescent ProteinsIBA 11/2018
1	Digoxin (Digitek)FDA LinkGeneric 01/2018
1	Aluminum Oxide (Sapphire)IBA 10/2016
1	SYBR Green IIBA 04/2016
1	Sepharose (Agarose)IBA 04/2016
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 04/2016
1	hippuryl-glycyl-glycine (HIGG)IBA 02/2016
1	Virus ReceptorsIBA 12/2015
1	2,6- diisopropyl- 4- (1- hydroxy- 2,2,2- trifluoroethyl)phenolIBA 09/2015
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 02/2015
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 02/2015
1	TOR Serine-Threonine KinasesIBA 02/2015
1	Mitogen-Activated Protein KinasesIBA 02/2015
1	Phenobarbital (Luminal)FDA Link 11/2014
1	ClathrinIBA 09/2013
1	rab5 GTP-Binding ProteinsIBA 09/2013
1	pitstop 2IBA 09/2013
1	Biological Warfare AgentsIBA 06/2011
1	Hemagglutinins (Hemagglutinin)IBA 01/2011
1	IronIBA 03/2007

Therapy/Procedure

7	Therapeutics 11/2022 - 05/2011
2	Euthanasia (Mercy Killing) 01/2023 - 01/2023
1	Off-Label Use 01/2019
1	Aftercare (After-Treatment) 07/2017